Neurocrine Biosciences, Inc. (NBIX) vs Viatris Inc. (VTRS)
- Neurocrine Biosciences, Inc. NBIX 135.71 −0.91%
- Viatris Inc. VTRS 18.66 +2.41%
Neurocrine Biosciences, Inc. and Viatris Inc. are both Drug Manufacturers Specialty & Generic companies. Viatris Inc. is the larger, with a market value of $20.9B against $13.9B — 1.5× the size. Viatris Inc. has negative trailing earnings, so its P/E is not meaningful; Neurocrine Biosciences, Inc. trades at 19.2×. Neurocrine Biosciences, Inc. grew revenue faster over the last twelve months: 34.4% against 4.40%. Neurocrine Biosciences, Inc. has the higher net margin (20.9% vs −2.79%) and the higher return on invested capital (15.0% vs −0.20%). Across the 21 metrics below, Neurocrine Biosciences, Inc. leads on 15 and Viatris Inc. on 6.
Valuation
Profitability
| Metric | NBIX | VTRS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 97.94% | 34.83% | 53.94% |
| Operating margin | 23.56% | (0.59%) | 0.00% |
| Net margin | 20.91% | (2.79%) | 0.00% |
| Free cash flow margin | 25.80% | 12.83% | 0.00% |
| Return on equity | 22.09% | (2.75%) | (0.40%) |
| Return on assets | 15.26% | (1.12%) | (3.32%) |
| Return on invested capital | 15.04% | (0.20%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack